ANVS:NYE-Annovis Bio Inc (USD)

COMMON STOCK | Biotechnology | NYE

Last Closing Price

USD 13.38

Change

+0.41 (+3.16)%

Market Cap

USD 0.11B

Volume

0.02M

Avg Analyst Target

USD 40.00 (+198.95%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


ANVS Stock Forecast & Price:
Based on the Annovis Bio Inc stock forecasts from 1 analysts, the average analyst target price for Annovis Bio Inc is USD 40.00 over the next 12 months. Annovis Bio Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Annovis Bio Inc is Bearish, which is based on 1 positive signals and 6 negative signals. At the last closing, Annovis Bio Inc’s stock price was USD 13.38. Annovis Bio Inc’s stock price has changed by +2.29% over the past week, +6.61% over the past month and -48.26% over the last year.

About Annovis Bio Inc (ANVS:NYE)

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-11-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO Novo Nordisk A/S

+0.96 (+0.81%)

USD259.38B 35.66 3.18
DNA Ginkgo Bioworks Holdings

+0.01 (+0.51%)

USD4.05B N/A -0.83
MYOV Myovant Sciences Ltd

-0.07 (-0.26%)

USD2.59B N/A -17.26
RCUS Arcus Biosciences Inc

-0.46 (-1.69%)

USD1.97B 21.91 10.97
BHVN Biohaven Pharmaceutical Holdin..

+0.44 (+2.86%)

USD1.05B N/A -2.48
ADGI Adagio Therapeutics Inc

N/A

USD0.50B N/A 0.19
ZYME Zymeworks Inc

-0.20 (-2.49%)

USD0.50B 300.20 -1.23
PFNX Pfenex Inc

N/A

USD0.44B 268.67 63.90
NUVB Nuvation Bio Inc

-0.01 (-0.54%)

USD0.40B N/A 2.16
ADCT Adc Therapeutics SA

-0.08 (-2.18%)

USD0.29B -99,999.99 -0.18

ETFs Containing ANVS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -23.89% 86% B 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -23.89% 86% B 28% F
Trailing 12 Months  
Capital Gain -48.06% 70% C- 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -48.06% 70% C- 11% F
Trailing 5 Years  
Capital Gain 89,100.00% 100% A+ 100% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 89,100.00% 100% A+ 100% A+
Average Annual (5 Year Horizon)  
Capital Gain 4,254.72% 100% A+ 100% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 4,254.72% 100% A+ 100% A+
Risk Return Profile  
Volatility (Standard Deviation) 10,638.10% 3% F N/A N/A
Risk Adjusted Return 40.00% 88% B+ 68% D+
Market Capitalization 0.11B 66% D 26% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -99,999.99 93% A 100% A+
Price/Book Ratio 3.53 30% F 23% F
Price / Cash Flow Ratio -11.59 90% A- 85% B
EV/EBITDA -2.61 78% C+ 82% B-
Management Effectiveness  
Return on Equity -73.60% 59% F 8% F
Return on Invested Capital -55.87% 55% F 5% F
Return on Assets -44.08% 30% F 2% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 3.50 70% C- 36% F
Short Percent 3.16% 48% F 54% F
Beta 1.24 47% F 33% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector